Community Research and Development Information Service - CORDIS

When inhibition leads to erection

Erection dysfunction is one of the most important complaints in modern society. Inhibition of the action of the PDE5 enzyme could provide a solution to this problem for more than 80% of cases. A French research team has synthesised a PDE5 inhibitor sixty times more effective than those that are currently provided in the market.
When inhibition leads to erection
Over 150 million men worldwide suffer from erectile dysfunction and although a number of diseases such as diabetes can be the cause, the underlying problem in most of these cases cannot be identified. However, nowadays drugs that intervene within the enzymes interaction mechanism could provide a solution to this problem for more than 80% of these cases.

A research team from the Louis Pasteur University synthesised a drug against erectile dysfunction that has significantly improved performance compared to existing treatments. This drug, similar to its competitors, reduces the action of an enzyme called PDE5. This enzyme plays a key role in the whole process of erection since it is the main controller of the blood that flows to and from the penis. Inhibiting the activity of the PDE5 enzyme means that more blood can flow to the penis and less leaves, which ultimately results in an erection.

The new drug inhibits PDE5 sixty times more effectively than current competitors. In this way a quicker response after the administration as well as increased duration of the drug's action can be achieved. This new drug will aim to compete with other similar drugs within a market worth more than 2 billion dollars, given that it meets the patients' requirements for quick response and longer action.
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top